1 near-penny stock I’m buying for the last time at 19p

Our writer explains why a penny stock he bought a couple of years ago has taken a big dip since Donald Trump was elected in November.

| More on:
British Pennies on a Pound Note

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

hVIVO (LSE: HVO) was a penny stock when I first bought it at 11p in late 2022. By July 2024, it spiked at 30p and I was sitting pretty (or so I thought).

The market cap had also surpassed £200m by then, disqualifying it from being called a penny stock. In the UK, those are often seen as stocks with a market cap under £100m as well as a share price beneath 100p.

Now, as I write (26 December), the share price has pulled back sharply to 19.56p. I’m still up, but I also bought shares in the summer at 29p and that purchase is down sharply too.

Should you invest £1,000 in BP right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BP made the list?

See the 6 stocks

To be fair, I knew what I was getting myself into, as small-caps and penny stocks are prone to stomach-churning bouts of volatility. This one’s certainly been no exception to the rule.

Yet I’m ready to take one last nibble on hVIVO shares in early January. Here’s why.

Created with Highcharts 11.4.3hVIVO Plc PriceZoom1M3M6MYTD1Y5Y10YALL28 Dec 201928 Dec 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

What is hVIVO?

For those unfamiliar, hVIVO is a firm that specialises in human challenge trials (HCTs), a growing niche market within the massive contract research organisation industry.

HCTs involve deliberately infecting healthy volunteers with a pathogen in a controlled environment to test treatments. The firm recruits these paid volunteers — many of them students in need of some cash — through its own FluCamp business.

hVIVO works with four of the top 10 global pharmaceutical companies. It conducted the world’s first Covid HCT during the pandemic, generating data that advanced understanding of the virus and helped guide vaccine development.

However, ‘vaccine’ has become a bit of a dirty word in some quarters following the US election.

Dark clouds

In November, Donald Trump nominated vaccine-sceptic Robert Kennedy Jr to lead the Department of Health and Human Services. We don’t know whether he’ll get the gig, but the market isn’t waiting to find out. The hVIVO share price is down 30% since then.

The fear seems to be that if major pharmaceutical companies anticipate a hostile regulatory or funding environment under Kennedy, they might reduce investments in vaccine-related projects. This could affect hVIVO’s pipeline of contracts and growth trajectory.

But the future still looks sunny

The truth is we don’t yet know how things will play out. What we do know however is that the company recently signed an £11.5m contract with an unnamed blue-chip pharmaceutical client to test a new antiviral candidate for respiratory syncytial virus (RSV).

This virus affects around 33m people annually, leading to approximately 4m hospitalisations worldwide and 101,000 deaths in children under five years old.

CEO Yamin ‘Mo’ Khan commented: “This contract further demonstrates the trust and confidence that leading pharmaceutical companies place in hVIVO’s human challenge study models.”

The study is scheduled to commence in H2 2025, with revenue recognised across 2025 and 2026. For 2024, management expects revenue of £62m, with a healthy EBITDA margin of around 22%-24%. And it’s targeting £100m in revenue by 2028.

hVIVO is an industry leader in human challenge trials, a market which is expected to grow from $100m-$150m today to as much as $1bn in the years ahead.

The business is highly cash generative and debt free. It’s even started paying a small dividend.

Lastly, with the stock on a forward price-to-earnings multiple of 11.7, the valuation looks very attractive.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in hVIVO Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Businesswoman calculating finances in an office
Investing Articles

Down 23% with a 6.5% yield, this FTSE 250 dividend gem looks undervalued to me!

Not many stocks on the FTSE 250 have a low valuation, high dividend yield, and solid growth potential. Our writer…

Read more »

Investing Articles

Is Tesla stock running out of road?

Tesla stock’s been tumbling over the past couple of months. This writer would like to own some -- but has…

Read more »

Investing Articles

£20,000 in savings? Here’s how it could be used to target a £278 monthly second income

Our writer illustrates how £20k could lay the foundations for a second income of several hundred pounds a month over…

Read more »

Photo of a man going through financial problems
Investing Articles

I asked ChatGPT to name the FTSE 250 share it would buy in a heartbeat – and it went mad!

Harvey Jones wondered whether artificial intelligence was up to the job of finding him a brilliant FTSE 250 share to…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Is the BP share price primed for lift off?

As an activist investor takes a substantial holding in BP, Andrew Mackie assesses what it will take to energise the…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

No savings? I’m using the 5-step Warren Buffett method as I aim to get rich

Christopher Ruane outlines a handful of investment techniques he uses, inspired by the incredible stock market record of Warren Buffett.

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With a spare £3,000, here’s how a new investor could start buying shares

Our writer explains how someone with a few thousand pounds and no prior stock market experience could start buying shares…

Read more »

UK money in a Jar on a background
Investing Articles

£10,000 invested in Greggs shares in 2020 has made this much passive income…

Greggs shares have struggled lately due to economic weakness and rising costs. Are they still worth considering for an ISA…

Read more »